Does perioperative use of aprotinin reduce the rejection rate in heart transplant recipients?

European Journal of Cardio-thoracic Surgery

Volumn 33, Issue 5, 2008, Pages 849-855

  Shuhaiber, Jeffrey H ^a   Goldsmith, Kimberley ^a   Large, Stephen R ^a   Tsui, Steven ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

Aprotinin; Heart transplantation; Rejection

Indexed keywords

AMPHOTERICIN B; APROTININ; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; GANCICLOVIR; MYCOPHENOLIC ACID; PENTAMIDINE; PREDNISOLONE; THYMOCYTE ANTIBODY; TRANEXAMIC ACID;

ADULT; ARTICLE; ASSISTED CIRCULATION; CARDIAC GRAFT REJECTION; COMBINATION CHEMOTHERAPY; DISEASE REGISTRY; DISEASE SEVERITY; DRUG SUBSTITUTION; FEMALE; GRAFT RECIPIENT; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; PNEUMOCYSTOSIS; POISSON DISTRIBUTION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; UNIVARIATE ANALYSIS;

ADULT; ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD LOSS, SURGICAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANEXAMIC ACID; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 41949134392     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2008.01.059     Document Type: Article

References (17)

1. Taylor D.O., Edwards L.B., Boucek M.M., Trulock E.P., Waltz D.A., Keck B.M., Hertz M.I., and International Society for Heart and Lung Transplantation. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report - 2006. J Heart Lung Transplant 25 8 (2006) 869-879
2. Lindenfeld J., Miller G.G., Shakar S.F., Zolty R., Lowes B.D., Wolfel E.E., Mestroni L., Page II R.L., and Kobashigawa J. Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. Circulation 110 24 (2004) 3734-3740
3. Royston D. Aprotinin therapy in heart and heart-lung transplantation. J Heart Lung Transplant 12 1 Pt 1 (1993) S19-S25
4. Sedrakyan A., Treasure T., and Elefteriades J.A. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 128 3 (2004) 442-448
5. Spray T.L. Use of aprotinin in pediatric organ transplantation. Ann Thorac Surg 65 6 Suppl. (1998) S71-S73 discussion S74-6
6. Roberts R.F., Nishanian G.P., Carey J.N., Darbinian S.H., Kim J.D., Sakamaki Y., Chang J.Y., Starnes V.A., and Barr M.L. Addition of aprotinin to organ preservation solutions decreases lung reperfusion injury. Ann Thorac Surg 66 1 (1998) 225-230
7. Bittner H.B., Richter M., Kuntze T., Rahmel A., Dahlberg P., Hertz M., and Mohr F.W. Aprotinin decreases reperfusion injury and allograft dysfunction in clinical lung transplantation. Eur J Cardiothorac Surg 29 2 (2006) 210-215
8. Wong R.L., Gutowski J.K., Katz M., Goldfarb R.H., and Cohen S. Induction of DNA synthesis in isolated nuclei by cytoplasmic factors: inhibition by protease inhibitors. Proc Natl Acad Sci U S A 84 1 (1987) 241-245
9. Stewart S., Winters G.L., Fishbein M.C., Tazelaar H.D., Kobashigawa J., Abrams J., Andersen C.B., Angelini A., Berry G.J., Burke M.M., Demetris A.J., Hammond E., Itescu S., Marboe C.C., McManus B., Reed E.F., Reinsmoen N.L., Rodriguez E.R., Rose A.G., Rose M., Suciu-Focia N., Zeevi A., and Billingham M.E. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24 11 (2005) 1710-1720
10. Stoica S.C., Atkinson C., Satchithananda D.K., Charman S., Goddard M., Redington A.N., and Large S.R. Endothelial activation in the transplanted human heart from organ retrieval to 3 months after transplantation: an observational study. J Heart Lung Transplant 24 5 (2005) 593-601
11. Lindenfeld J., Miller G.G., Shakar S.F., Zolty R., Lowes B.D., Wolfel E.E., Mestroni L., Page II R.L., and Kobashigawa J. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation 110 25 (2004) 3858-3865
12. Koch A., Burgschweiger A., Herpel E., Sack F.U., Schirmacher P., Szabo G.B., Karck M., and Schnabel P.A. Inducible NO synthase expression in endomyocardial biopsies after heart transplantation in relation to the postoperative course. Eur J Cardiothorac Surg 32 4 (2007) 639-643
13. Bittner H.B., Binner C., Dahlberg P., and Mohr F.W. Reducing ischemia-reperfusion injury in clinical lung transplantation. Transplant Proc 39 2 (2007) 489-492
14. Prendergast T.W., Furukawa S., Beyer III A.J., Eisen H.J., McClurken J.B., and Jeevanandam V. Defining the role of aprotinin in heart transplantation. Ann Thorac Surg 62 3 (1996) 670-674
15. Henry DA, Moxey AJ, Carless PA, O'Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001;(1):CD001886.
16. Karkouti K., Beattie W.S., Dattilo K.M., McCluskey S.A., Ghannam M., Hamdy A., Wijeysundera D.N., Fedorko L., and Yau T.M. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 46 3 (2006) 327-338
17. Fernandez F.G., Jaramillo A., Ewald G., Rogers J., Pasque M.K., Mohanakumar T., and Moazami N. Blood transfusions decrease the incidence of acute rejection in cardiac allograft recipients. J Heart Lung Transplant 24 7 Suppl. (2005) S255-S261